Single photon emission tomography imaging in parkinsonian disorders: a review

Paul D. Acton* and P. David Mozley
Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA

Parkinsonian symptoms are associated with a number of neurodegenerative disorders, such as Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Pathological evidence has shown clearly that these disorders are associated with a loss of neurons, particularly in the nigrostriatal dopaminergic pathway.

Positron emission tomography (PET) and single photon emission tomography (SPECT) now are able to visualise and quantify changes in cerebral blood flow, glucose metabolism, and dopaminergic function produced by parkinsonian disorders. Both PET and SPECT have become important tools in the differential diagnosis of these diseases, and may have sufficient sensitivity to detect neuronal changes before the onset of clinical symptoms. Imaging is now being utilised to elucidate the genetic contribution to Parkinson’s disease, and in longitudinal studies to assess the efficacy and mode of action of neuroprotective drug and surgical treatments.

This review summarises recent applications of SPECT imaging in the study of parkinsonian disorders, with particular reference to the increasing role it is playing in the understanding, diagnosis and management of these diseases.

1. Introduction

Parkinson’s disease (PD) (paralysis agitans) is a neurodegenerative disorder which affects over one million people in North America, and is associated with clinical symptoms of motor deficit, such as tremor, rigidity, hypokinesia and bradykinesia [101]. It is one of a family of such diseases associated with the loss of central-nervous system neurons, such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).

Discrimination of these diseases is important as each has a different prognosis, requiring distinct treatment regimens, particularly early in the course of the disease [127].

Post-mortem studies have indicated clearly that these parkinsonian disorders exhibit dramatic losses of various neurons, particularly the dopaminergic neurotransmitter system in the nigrostriatum [63,71]. The predominant cause of parkinsonism is PD, accounting for up to 85% of all reported cases. Pathological findings show that early in PD the majority of neuronal loss takes place in the ventrolateral tier of the substantia nigra, which projects to the posterior putamen [48]. This leaves the ventral putamen and caudate relatively spared in the early stages of the disease. In addition, PD is characterised by the formation of neuronal Lewy bodies.

MSA accounts for up to 10% of patients presenting with parkinsonian symptoms. It exhibits much more widespread disruptions in the brain, with symptoms associated with extrapyramidal, pyramidal, autonomic and cerebellar involvement, and is characterised by degeneration and gliosis in the brain stem, spinal cord, striatum, globus pallidus and cerebellum [126,133]. While most MSA patients do not respond to dopaminergic therapy, the disease exhibits neurodegeneration in the nigrostriatum similar to that observed in PD.

The neuronal loss in PSP is also comparable to PD, but without the formation of Lewy bodies. Degeneration occurs primarily in the brain stem and striatum, with the formation of neurofibrillary tangles [125].

Other important confounds in the differential diagnosis of PD include dopa-responsive dystonia and essential tremor. Dopa-responsive dystonia is an inherited disorder which presents with clinical symptoms very similar to early-onset PD [118]. However, PET and SPECT studies have shown either normal or only slight reductions in dopaminergic function, which is in marked contrast to PD [33,61,116,119,155]. Essential tremor presents with clinical symptoms of postural tremor of approximately 7 Hz, usually involving the hands or forearms. Some similarities between the clin-
tical symptoms of PD and essential tremor can lead occasionally to misdiagnosis, although PET and SPECT studies have shown clearly there is no loss of dopaminergic neurons in patients with essential tremor [13,26,88].

Until recently, positron emission tomography (PET) and single-photon emission tomography (SPECT) imaging in neurodegenerative disorders have focussed on providing differential diagnosis between patients and healthy control subjects, and also between the different types of parkinsonian disorders. Indeed, it may be that the differential diagnosis of neurodegenerative diseases will provide the first routine clinical application for neureceptor and transporter binding studies. However, more recently, imaging studies are becoming increasingly important in understanding the pathogenesis of neurodegenerative disease, and in deciphering any genetic contribution to these disorders. In addition, they are being utilised in longitudinal studies to assess the efficacy of surgical and neuroprotective therapies.

This review discusses the contributions of PET and SPECT imaging on the diagnosis, understanding, and management of parkinsonian disorders, with particular emphasis on SPECT. Although PET has been used for longer and in more applications than SPECT, single-photon imaging is beginning to make important advances in the field, and in those applications where PET still dominates, the potential contributions from SPECT have been described.

2. Imaging in the differential diagnosis of parkinsonian disorders

The differential diagnosis of the various parkinsonian disorders based on clinical symptoms alone is difficult [57,134,161]. Tremor is a classic feature of PD, although this can also be found in patients with PSP and MSA. Similarly, a general criteria for diagnosing PD is a good, sustained response to levodopa (L-DOPA) therapy, although, again, this is also found in some patients with MSA and dopa-responsive dystonia. Post mortem studies have shown that the clinical diagnosis of Parkinson’s disease is incorrect in almost half the cases diagnosed by general neurologists. The error rate is still thought to exceed 25% when the diagnosis is made by a subspecialist in movement disorders. These observations, which do not appear to be disputed by practicing clinicians, have contributed to the motivation for developing functional neuroimaging techniques that can differentiate between these disorders.

Structural changes induced by parkinsonian diseases are generally small, and often only evident when the disease is into an advanced stage. Consequently, the diagnostic accuracy of anatomical imaging modalities (e.g. magnetic resonance imaging, MRI) in neurodegenerative disorders is poor [145]. In general, PET and SPECT imaging have provided a better platform for the diagnosis of parkinsonian disorders. Functional imaging of neurodegenerative disease with PET and SPECT has followed two main paths; studies of blood flow and cerebral metabolism to detect abnormal tissue functioning, or imaging of the dopaminergic neurotransmitter system to study the loss of dopamine neurons.

PET studies of cerebral glucose metabolism have used the glucose analogue [18F]fluorodeoxyglucose ([18F]FDG), while the SPECT tracers [99mTc]hexamethylpropylene amine oxime ([99mTc]HMPAO) and [99mTc]ethylcysteinate dimer ([99mTc]ECD) are markers of cerebral perfusion. Striatal glucose metabolism and perfusion are generally found to be normal in PD [75,100,122,154,172], although some studies have demonstrated an asymmetry of striatal metabolism [38]. Interestingly, atypical parkinsonian disorder has been differentiated from idiopathic PD by the appearance of striatal metabolic abnormalities in the atypical group [6]. Many studies have shown more global cortical hypometabolism or hypoperfusion, or a loss of posterior parietal metabolism with a pattern similar to that observed in Alzheimer’s disease [42,93,100,130,172]. Others have used the differences in regional metabolism or cerebral blood flow to discriminate between PD and MSA [122,123] or PSP [37]. However, in general, the diagnostic accuracy of cerebral blood flow and glucose metabolism in differentiating neurodegenerative disorders is relatively poor in comparison to direct imaging of the dopaminergic nigrostriatal pathway. This may be particularly true in Parkinson’s patients with dementia. Studies of blood flow and glucose metabolism in patients with pure Lewy body disease with no features of Alzheimer’s disease have consistently shown bi-parietal, bi-temporal hypometabolism, a pattern that was once thought to represent the signature of Alzheimer’s.

A variety of tracers exist for the study of the dopaminergic neurotransmitter system using both PET and SPECT (see Table 1). Early PET studies of the nigrostriatal pathway used the uptake of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) as a measure of the integrity of dopamine neurons [51,52]. [18F]FDOPA measures changes in striatal dopa decarboxylase activity, which is dependent on the availabili-
ity of striatal dopaminergic nerve terminals and is proportional to the number of dopamine neurons in the substantia nigra [156].

Direct measurements of dopamine transporter binding sites are possible with \textsuperscript{11}C]cocaine [50], or the cocaine analogues 2β-carbomethoxy-3β-[4-iodophenyl] tropane (β-CIT) and N-ω-fluoropropyl-2β-carbomethoxy-3β-[4-iodophenyl] tropane (FP-CIT), labelled with either \textsuperscript{18}F or \textsuperscript{11}C for PET or \textsuperscript{123}I for SPECT [96, 117]. Other dopamine transporter ligands include N-[3-iodopropen-2-yl]-2β-carbomethoxy-3β-[4-chlorophenyl] tropane (IPT) [82], its 4-fluorophenyl analogue [\textsuperscript{123}I]altropane [95], 2β-carbomethoxy-3β-[4-fluorophenyl] tropane (\textsuperscript{13}C)CFT) [34], and \textsuperscript{11}C]d-threo-methylphenidate [170]. Of particular importance is the recent development of the first successful \textsuperscript{99m}Tc-labeled dopamine transporter ligand, \textsuperscript{99m}Tc-TRODAT-1 [80, 83]. Since \textsuperscript{99m}Tc is so much more widely available and less expensive than \textsuperscript{123}I, this new tracer could move imaging of the dopaminergic system from a research environment into routine clinical practice, particularly with simplified imaging protocols [1].

Several tracers exist for imaging postsynaptic dopamine D\textsubscript{2} receptors, using radioactively labelled dopamine receptor antagonists. The most widely used for SPECT include S-(−)-3,5-dichloro-N-[(1-ethyl-2-pyridylindinyl)] methyl-2-hydroxy-6-methoxybenzamide (\textsuperscript{11}C]raclopride) [43] and \textsuperscript{11}C] or \textsuperscript{18}F-N-methylspiroperidol [10,151].

PET and SPECT studies of radiotracer binding to postsynaptic dopamine receptors and presynaptic dopamine transporters and neurons have proved to be powerful techniques for quantifying the loss of dopaminergic neurons in normal aging [7,35,102,112, 113,142,166,169,171], PD [12,18,19,21,23,25,49,69, 89,114,115,149,159,160,164] and other neurodegenerative disorders [8,28,31,56,59,105,131,165] (see Table 2). Studies of neuronal degeneration associated with the effects of normal aging have indicated that, while dopamine transporter concentrations decrease as a natural consequence of aging, the changes are small compared with the effects of disease (Fig. 1) [112]. PET and SPECT studies have indicated a consistent pattern of dopaminergic neuronal loss in PD, usually with more pronounced depletion in the putamen rather than in the caudate (Figs 2 and 3). In addition, there is frequently a marked asymmetry, particularly in the early stages of the disease, and a good correlation with symptom severity [159] and illness duration [114]. Most importantly, imaging studies may be sensitive enough to detect very early PD [18,109,163], perhaps even before clinical symptoms become apparent.

Characteristically, PD begins with unilateral symptoms of motor deficit, which gradually progress bilaterally over time. Studies of patients with early hemi-PD have shown that, despite the subject only exhibiting one-sided clinical symptoms, the PET and SPECT findings demonstrated bilateral decreases in tracer binding, with a greater reduction in the side contralateral to the clinical signs [2,18,99,135]. The ability of PET and

Table 1

<table>
<thead>
<tr>
<th>Binding site</th>
<th>PET or SPECT</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dopamine synthesis</strong></td>
<td>\textsuperscript{18}F]DOPA</td>
<td>PET \cite{51,52}</td>
</tr>
<tr>
<td><strong>Dopamine transporters</strong></td>
<td>\textsuperscript{[11]C]cocaine}</td>
<td>PET \cite{50}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[11]C} \textsuperscript{[18]F}]\textsuperscript{[123]I}β-CIT</td>
<td>Both \cite{117}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[11]C} \textsuperscript{[18]F}]\textsuperscript{[123]I}FP-CIT</td>
<td>Both \cite{96}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[123]I]IPT}</td>
<td>SPECT \cite{82}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[123]I]altropane}</td>
<td>SPECT \cite{95}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[11]C]CFT}</td>
<td>PET \cite{34}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[11]C]methylphenidate}</td>
<td>PET \cite{170}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[99m}Tc\textsuperscript{]TRODAT-1}</td>
<td>SPECT \cite{80,83}</td>
</tr>
<tr>
<td><strong>Dopamine D\textsubscript{2} receptors</strong></td>
<td>\textsuperscript{[123]I]IBZM}</td>
<td>SPECT \cite{78,79,81}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[123]I]IBF}</td>
<td>SPECT \cite{14,48}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[123]I]epidepride}</td>
<td>SPECT \cite{67,68}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[11]C]raclopride}</td>
<td>PET \cite{43}</td>
</tr>
<tr>
<td></td>
<td>\textsuperscript{[11]C] \textsuperscript{[18]F}]N-methylspiroperidol</td>
<td>PET \cite{10,151}</td>
</tr>
</tbody>
</table>
Table 2
Summary of PET and SPECT measurements of neurodegenerative and parkinsonian disorders

<table>
<thead>
<tr>
<th>Syndromes</th>
<th>Dopamine transporters in caudate</th>
<th>Dopamine transporters in putamen</th>
<th>Postsynaptic dopamine receptors</th>
<th>Blood flow and metabolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson’s disease</td>
<td>Normal or slight loss</td>
<td>Loss</td>
<td>Normal or upregulated</td>
<td>General reduction – striatum normal</td>
</tr>
<tr>
<td>Multiple system atrophy</td>
<td>Normal or slight loss</td>
<td>Loss</td>
<td>Loss</td>
<td>Reduced in contralateral putamen</td>
</tr>
<tr>
<td>Progressive supranuclear palsy</td>
<td>Loss</td>
<td>Loss</td>
<td>Normal or slight loss</td>
<td>Reduced in cortex and striatum</td>
</tr>
<tr>
<td>Dopa-responsive dystonia</td>
<td>Normal</td>
<td>Normal</td>
<td>Increase</td>
<td>?</td>
</tr>
<tr>
<td>MPTP exposure</td>
<td>Loss</td>
<td>Loss</td>
<td>Loss in caudate?</td>
<td>?</td>
</tr>
<tr>
<td>Essential tremor</td>
<td>Normal</td>
<td>Normal</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>

Fig. 1. Age-related decline in the concentrations of dopamine transporters in the striatum, compared with the much greater loss of transporters due to Parkinson’s disease, measured with \[^{99m}Tc\]TRODAT-1 and SPECT [112]. The straight line represents a “broken-stick” model fit to the control data, indicating that the loss of dopamine transporters with normal aging occurs in two distinct phases, with a break-point age around 36 years.

SPECT to detect presymptomatic PD may have important consequences for screening of familial PD, and also in the measurement of the efficacy of neuroprotective therapies.

Although most of the PET and SPECT imaging studies have shown highly significant differences between groups of Parkinson’s patients and age-matched normal controls, the statistically significant differential diagnosis of an individual subject is more problematic. Patients with severe PD are easily separated from healthy controls even from a simple visual inspection of striatal images, which can be quantified using some form of discriminant analysis [31,114,143,163], which has a sensitivity and specificity close to 100% in the proper
clinical setting. However, patients presenting much earlier in the course of the disease are more difficult to detect, with potentially significant overlap with an age-matched control group [109,138] and consequential loss of diagnostic accuracy. The situation may be further complicated if the early differential diagnosis between several neurodegenerative disorders is required. Many of the symptoms associated with parkinsonian disorders are non-specific, which is why the accurate clinical diagnosis of these diseases is difficult. Indeed, some histopathological studies have shown that as many as 25% of all patients who were diagnosed with PD before death had been misdiagnosed [57,134]. Studies have shown little difference between radiotracer binding to dopamine transporters in patients with PD and MSA or PSP [28,31]. Based on current methods of analysis, it appears that the detection of early PD, or the differential diagnosis between various neurodegenerative disorders, may not be possible in individual cases based on imaging of a single neurotransmitter system alone [19]. However, recent developments in the automated, pixel-based analysis of PD may improve the sensitivity of imaging techniques [2,54].

The relative merits of anatomical and functional imaging have been combined in some studies which utilize either several different radiotracers, or data
Fig. 4. SPECT image of $^{123}$I-FP-CIT binding to dopamine transporters in a patient with MSA. Note the similarity between this image and the images of subjects with PD using the same tracer (Fig. 3) which complicates the differential diagnosis (image courtesy of Dr. Jim Patterson, Institute of Neurological Sciences, Glasgow).

Fig. 5. SPECT images of $^{123}$I-IBZM binding to postsynaptic dopamine D$_2$ receptors in patients with PD (top row) and MSA (bottom row). Although there is some evidence of striatal degeneration of postsynaptic receptors in MSA, a diagnosis by visual inspection alone can be difficult (image courtesy of Dr. Jim Patterson, Institute of Neurological Sciences, Glasgow).

from both MRI and PET or SPECT. Regional glucose metabolism has been studied in parkinsonian disorders with $^{18}$F-FDG and PET, and the data combined with striatal $^{18}$F-fluorodopa uptake measurements to give an improved diagnostic indicator, and a better understanding of the underlying disease processes [17,44, 123]. However, it should be noted that the improvement was relatively small over the good predictive capabilities of $^{18}$F-fluorodopa by itself in these patient groups. Some studies have utilized the complementary information coming from structural MRI and functional $^{18}$F-FDG PET in distinguishing between patients with MSA and control subjects [62,77], where both focal MRI hypointensities and reduced glucose metabolism occurred on the side contralateral to clinical symptoms. Other studies have combined data from MRI and postsynaptic dopamine receptor concentrations using $^{123}$I-IBZM and SPECT, giving useful in-
formation on the involvement of multiple brain regions in PSP [11] and MSA [146].

However, the greatest discrimination between various neurodegenerative disorders may be found using PET or SPECT imaging of both pre- and postsynaptic dopamine binding sites. A study of [123I]-β-CIT and [123I]IBZM binding in patients with early PD showed marked unilateral reductions in dopamine transporters measured by [123I]-β-CIT concomitant with elevated dopamine D2 receptor binding of [123I]IBZM [174]. Recent SPECT studies investigating pre- and postsynaptic dopamine binding sites in the differential diagnosis of PD, MSA and PSP have shown promising results, with a reduction in dopamine transporter availability in all diseases, and some discrimination between disorders in the pattern of dopamine D2 receptor concentrations [70] (Figs 4 and 5). Similar results were observed in a PET study of early Parkinson’s patients, where striatal [18F]fluorodopa uptake was reduced and [11C]raclopride binding was upregulated, with the degree of increase in dopamine transporter binding inversely proportional to disease severity [9]. This study also used [18F]FDG imaging of the same patients to determine the optimum combination of neuroreceptor function and glucose metabolism to differentiate between healthy controls, and patients with PD [9] or MSA [8]. The results suggest that striatal [18F]FDG and particularly [11C]raclopride are sensitive to striatal function and may help with the characterization of patients with MSA, whereas [18F]fluorodopa can accurately detect nigrostriatal dopaminergic abnormalities consistent with parkinsonian disorders.

SPECT imaging of both pre- and postsynaptic dopamine binding sites simultaneously has now been performed in non-human primates, using [99mTc]TRODAT-1 and [123I]IBZM, separating the two radio tracers based on their different energy spectra [40]. The possibility of simultaneously imaging both dopamine transporters and D2 receptors in neurodegenerative disorders is an exciting prospect, providing a unique probe in the investigation and diagnosis of these diseases.

3. Longitudinal imaging studies in parkinsonian disorders

The majority of PET and SPECT imaging studies in parkinsonian disorders have concentrated on differentiating between the various diseases. However, more recently, follow-up longitudinal studies of patient groups have been undertaken, providing important insights into the rate of progression of disease, and also enabling estimates of the duration of the preclinical phase. Both PET and SPECT imaging have shown they are sufficiently reproducible and sensitive to measure changes in dopaminergic function consistent with the progression of neurodegenerative disease.

Longitudinal PET and SPECT studies have been performed on patients with PD [20,98,107,110,111,148,167], and MPTP-induced parkinsonian disorder [168]. All longitudinal studies have shown that the rate of deterioration of dopaminergic neurons is much greater in PD than that associated with the effects of normal aging, although the estimates of the mean rate of disease progression vary quite widely. Using PET and [18F]DOPA, the rates of neuronal loss have been estimated to range from 0.5% of the normal per year [167] up to 7% of the normal per year [110], although this depends strongly on the method of analysis and the striatal region being studied [107]. Recent SPECT studies have demonstrated relatively consistent reductions in dopamine transporter binding between 7–11% per year [20,148], although these data are still preliminary. Extrapolating back to the time of onset of clinical symptoms, the magnitude of neuronal loss required before external clinical signs become apparent has been estimated to be 75% of normal in the putamen, and 91% of normal in the caudate [107], which is in approximate agreement with studies of the asymptomatic side in hemi-PD [22]. Extrapolating beyond the threshold for clinical symptom onset, the same study estimated that the mean pre-clinical period (the time between disease onset and symptom onset) was less than 7 years [107]. These results have important consequences for models of disease pathogenesis and progression.

4. Imaging in the pathogenesis of PD

Many neurotoxins and neurological traumas which damage the basal ganglia and substantia nigra produce clinical symptoms of parkinsonian disorders. One well-known toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) appears to target with high specificity those neurons that are involved in PD, and has been utilised in animal models of the disease.

The mechanism of MPTP neurotoxicity may shed some light on the pathogenesis of PD and other neurodegenerative disorders [73]. MPTP is highly lipophillic, and crosses the blood-brain barrier where it is oxidised to MPP⁺. Although MPTP itself does not appear to be toxic, the oxidised product MPP⁺ is
taken up by the dopamine transporter protein, where it is actively transported into dopaminergic nerve terminals [153]. Once inside the presynaptic neuron, MPP⁺ is a potent toxin resulting in neuronal cell death.

This mechanism for MPTP neurotoxicity has led to the suggestion that Parkinsonian disorders may be caused by other toxins, whether endogenous or acquired from the environment [104]. It may be a predisposition to producing endogenous toxins that introduces a genetic aspect to PD. A prime candidate for these neurotoxins are free radicals, which may cause neuronal injury through a number of mechanisms, including excitotoxicity, metabolic dysfunction, and interference with intracellular calcium [32,47,60,150].

The central role of dopamine reuptake sites in the transport of the toxin into the neuron has been investigated recently, using SPECT imaging of [123I]β-CIT binding in normal controls and patients with PD [148]. It is hypothesised that, if the transport of endogenous toxins by dopamine transporters into the neuron causes cell death, then a patient with a greater initial concentration of functioning transporters should degenerate faster due to the increased uptake of neurotoxins. Consequently, an initial SPECT scan of the concentration of available dopamine reuptake sites should be a good marker for the rate of progression of the disease, monitored by a follow-up scan some time later. This was found to be the case, where among PD patients the reduction in [123I]β-CIT binding in sequential scans was highly correlated with the initial scan [123I]β-CIT uptake [148]. This is the first evidence from in vivo imaging that neurotoxin uptake may be implicated in the pathogenesis of PD.

The genetic contribution to the etiology of neurodegenerative Parkinsonian disorders is still unclear, although it is now believed that heredity plays an important role in PD. Early twin studies did not suggest a genetic contribution [41,173]. However, it now appears that genetic factors may confer some degree of susceptibility to PD [97], particularly in light of some recent PET studies in twins [30,128] and in families in which clinically asymptomatic relatives of PD sufferers exhibited signs of striatal degeneration [129,144]. These studies have shown very effectively the potential for PET and SPECT screening of subjects at risk from familial PD.

5. Imaging in the drug treatment of PD

The management and treatment of PD with dopamine replacement therapies has been tremendously successful for many patients. L-DOPA and dopamine receptor agonists are extremely efficacious in reducing the clinical symptoms associated with PD. However, their effectiveness can decrease over time, with the development of some side-effects and the characteristic "on-off" periods [86,87]. Medication refractory periods of severe bradykinesia and rigidity tend to increase in frequency and severity with time [106], and can alternate with disabling dyskinesias and dystonias. While there are a number of promising neuroprotective drugs in development which may delay the onset of these symptoms, about half of all patients begin to suffer from these sequelae in less than five years.

It is the deficit of striatal dopamine that induces the motor symptoms in PD, hence several potential treatment mechanisms operate by increasing the quantity of endogenous dopamine. L-DOPA is the amino acid precursor which is decarboxylated in the synthesis of dopamine in the brain. It has been used for many years to treat PD in the form of dopamine replacement therapy. However, the undesirable side-effects of L-DOPA treatment, together with a gradual decline in its efficacy over time, has led to the development of further drug treatments to either delay the onset of side-effects, or to delay the need for conventional L-DOPA therapy. The main targets of the newer drugs for PD are two important enzymes in the metabolism of dopamine, namely monoamine oxidase-B (MAO-B) and catechol-O-methyltransferase (COMT) [15]. The inhibition of dopamine metabolism enhances its availability at postsynaptic receptor sites, reducing or removing the need for L-DOPA replacement therapy. Several MAO-B and COMT inhibitors have been shown clinically to reduce the effects of the classic “on-off” behaviour of L-DOPA therapy, in addition to enhancing its efficacy [127,162]. It has also been suggested that these agents may confer some neuroprotective property, by slowing cell death. Similarly, other neuroprotective agents have been proposed which scavenge the free radicals and reduce or even reverse the effects of neuronal degeneration [29,58,136,175].

However, it is unclear whether these drugs operate solely by enhancing the levels of endogenous dopamine, or by a true neuroprotective quality in slowing down or reversing the degeneration of dopamine neurons [72]. Clinical studies alone cannot determine whether these drugs exhibit genuine neuroprotective properties, or simply increase available dopamine. Indeed, it has been suggested that L-DOPA treatment, despite its clinical efficacy, may actually accelerate the degeneration of the dopaminergic neurons by increas-
ing the levels of free radicals through dopamine auto-
oxidation [120,121,175], although others have ques-
tioned this theory [3]. However, since L-DOPA de-
creases the clinical signs of PD, it would be very dif-
ticult to show clinically that L-DOPA actually does ac-
celerate neuronal cell death.

Consequently, a quantitative means for the in vivo
imaging of dopaminergic neurons would provide a vi-
tal probe to examine the mode of action and efficacy
of various drugs in the treatment of PD. PET and
SPECT could be used to determine whether the neu-
roprotective therapies are genuinely slowing the de-
generation of dopaminergic neurons, or simply alter-
ing levels of endogenous neurotransmitter [108]. Both
PET and SPECT imaging of the dopaminergic system
have exquisite sensitivity to detect and measure subtle
the 
changes in neuronal integrity, and have been used in
longitudinal studies to monitor the progression of dis-
ease in PD [20,107,148,167] and other parkinsonian
diseases [56]. Comparisons between dopamine D2 re-
ceptor availability, measured with \(^{123}\)IIBZM SPECT,
and long-term clinical follow-up showed a strong cor-
relation between initial \(^{123}\)IIBZM binding and the re-
sponse to L-DOPA therapy, and also to the likelihood
of developing non-PD clinical symptoms [147]. The
ability of SPECT imaging to predict those subjects that
will respond to certain therapies is a vital tool in the
clinical management and prognosis of patients with PD
and other parkinsonian diseases.

There are currently many studies in progress which
use these imaging techniques to monitor changes in
the dopaminergic system, and soon they will be able to
shed some light on the efficacy and neuroprotective
qualities of these therapies.

6. Imaging in the surgical treatment of PD

Several neurosurgical procedures have been devel-
oped over a number of years to treat patients with PD,
particularly those who exhibit poor or declining re-
sponse to conventional L-DOPA drug therapy.

At this time, the most common surgical interven-
tion for the palliation of tremor remains thalidotomy,
whereas for the palliation of dyskinesias and off pe-
riods it is pallidotomy [85]. Pallidotomy is designed
to reduce the hyperactivity in the internal segment of
the globus pallidus caused by excessive input from the
subthalamic nuclei [153]. This benefits the motor dis-
abilities associated with PD, as it is postulated that stri-
atal dopamine deficiency produces an overactive medial
globus pallidus as a result of the disinhibition of gluta-
matergic projections from the subthalamic nuclei to the
globus pallidus. However, the mechanisms underlying
the efficacy of pallidotomy are not well understood,
and it is also associated with some risk of cognitive and
visual morbidity. Imaging studies of patients undergo-
ing pallidotomy have been performed, although they
have been limited to measurements of cerebral blood
flow [53,140] and metabolism [4,45,46,66] using PET
and \(^{18}\)O and \(^{18}\)FDG respec-tively. However, these
studies have indicated promising results in the capability
of functional imaging to predict the outcome of pal-
idotomy [4,66], and correlate with the improvements
in functional ability [45,66]. Future PET and SPECT
studies of pre- and post-operative dopaminergic func-
tion should refine these results, and give important clues
to the nature of the beneficial effects of pallidotomy.

An exciting alternative to pallidotomy is the electro-
cal stimulation of the subthalamus [39,76,90,91,132].
Although the mechanism of action of subthalamic stim-
ulation is not fully understood, it is believed to be con-
ceptually related to pallidotomy, in that the source of
overstimulation to the globus pallidus is removed by
electrical pulses. Subthalamic stimulation is achieved
by the insertion of electrodes into the brain, with an
external pulse generator whose frequency and duration
can be modulated to suit the individual. This tech-
nique is less invasive than pallidotomy, and it is also
reversible. However, like any neurosurgical procedure,
it involves some degree of risk, such as cognitive degra-
dation in a few patients [76]. Open and double-blind
evaluations of the technique suggest that it is capable of
slowing the progression of PD [86]. Favorable assess-
ments have been based primarily on subjective descrip-
tions of symptom severity tracked with patient diaries
and clinical rating scales [86]. As compelling as these
descriptions are, and as useful as these subjective mea-
sures have been in assessing changes within patients,
there have not been many objective ways of comparing
results between groups of patients treated with different
operations and protocols, such as variable schedules or
stimulation at different frequencies.

A third surgical methodology, developed relatively
recently, involves the transplantation of fetal tissue into
the nigrostriatal dopaminergic pathway, either using
tissue from aborted human fetuses [92] or from ani-
mals [36]. The concept behind this technique is that the
grafted fetal nigral cells will survive and reinnervate the
striatum, replacing the dopaminergic striatal neu-
rons lost in PD. To assess the efficacy of fetal grafts in
PD, several studies have used \(^{18}\)FDOPA PET to mea-
sure any increases in dopaminergic function following surgery [24,74,92,137,141,158]. While only small numbers of patients have been studied thus far, the utility of PET and, in the future, SPECT in assessing the response to fetal transplant appears very promising.

Clinical measures of the outcome of these surgical techniques have indicated that pallidotomy may have the best results, but some investigators conclude that “the role of surgery in managing other levodopa-resistant problems is controversial, and to date there are no convincing reports demonstrating a benefit” [87]. The potential morbidity as well as the costs of these operations require systematic and longitudinal assessments of their efficacy, a role for which PET and SPECT imaging of the dopaminergic system is uniquely capable [24].

7. Imaging of non-dopaminergic neurons in PD

Although the majority of studies investigating neuronal changes caused by parkinsonian diseases have focussed on the dopaminergic system, another neurotransmitter is believed to be intimately linked to the pathogenesis of PD, namely glutamate (NMDA) (see [87] for a detailed explanation of the various neurotransmission pathways thought to be involved in PD). NMDA is an excitatory amino acid, and has been implicated as the neurotransmitter which causes excitotoxicity in the pathophysiology of PD [16,55,94,139,157]. NMDA induces excitotoxicity in the presence of impaired cellular energy metabolism, which may be just the environment produced in dopaminergic neurons in the substantia nigra pars compacta by PD. Dopamine deficiency in PD causes disinhibition and overactivity of the subthalamic nuclei, which project to the external and internal segments of the globus pallidus and the substantia nigra. Neurons from the subthalamus are excitatory, using NMDA as a neurotransmitter, and innervate dopaminergic neurons in the substantia nigra pars compacta that contain NMDA receptors. Hence, disinhibition of the subthalamic nuclei neurons caused by PD may induce NMDA excitotoxic damage in target structures, such as the substantia nigra pars compacta. This scenario of dopamine loss augmenting subthalamic activity, which, in turn, causes further NMDA-induced damage to dopamine neurons creates the ideal environment for an increasing cycle of neuronal cell death.

The role of NMDA, and a possible dysfunction of the NMDA receptor in PD makes it an important target for new neuroprotective treatments. In particular, the modulation of NMDA receptor-mediated neurotransmission may provide an exciting alternative to dopaminergic drug therapies [16,55,94,139]. However, the role of NMDA receptors in PD requires investigation with imaging techniques to measure any changes in NMDA function as a result of disease, or to study NMDA excitotoxicity as a mechanism in the initial onset of PD.

The development of specific agents for imaging the NMDA receptor is still in its infancy, with just a small number of potential ligands under development for PET and SPECT. [11C]ketamine exhibited relatively poor brain uptake in animal studies, probably due to its rapid metabolism [152]. Preliminary results for a recently developed tracer, [18F]1-amino-3-fluoromethyl-5-methyl-adamantane ([18F]FAFA), are much more promising, with high brain uptake in mice and a cerebral distribution consistent with the known concentrations of NMDA receptors [5]. A SPECT tracer, [123I]MK-801 also has shown promise, although it exhibits a high degree of non-specific binding due to high lipophilicity [27,124]. However, further NMDA SPECT ligands are currently in the late stages of development [103].

Another neurotransmitter, gamma-aminobutyric acid (GABA), is a major component of the neural pathways involved in motor function. GABA is an inhibitory neurotransmitter, and is involved in the transmission of signals from the striatum to the globus pallidus and into the subthalamic nuclei. It also provides control over the thalamic nuclei and brain stem from the internal globus pallidus and substantia nigra reticulata. Because these structures use the inhibitory neurotransmitter GABA, the increased glutamatergic-driven input resulting from PD causes excessive GABAergic inhibition, which leads to an effective shutdown of the thalamic and brain stem nuclei [87]. This inhibition leads to suppression of the motor cortex and brain stem locomotor areas, which may cause many of the motor deficits inherent in PD.

Despite the widespread and vital role of the GABAergic system in PD, very few imaging studies of the GABA system have been performed. However, a recent Japanese study, using the SPECT ligand [123I]iomazenil, demonstrated a pronounced impairment of cortical GABAergic function in PD, with the reduction in [123I]iomazenil binding directly correlated with motor disability [64,65].
8. Future directions

There are a large number of imaging techniques which can be used to attempt to differentiate between the various neurodegenerative disorders. Taken in isolation, many of them can diagnose PD, MSA and PSP with some success. However, the diagnosis at an early stage in the progression of each disease, possibly even before clinical symptoms have become apparent, is much more difficult, and may require multiple imaging modalities or combinations of tracers. The widespread availability of SPECT imaging, perhaps combined with newer and less expensive tracers, may lead to the routine implementation of SPECT scanning in the diagnosis of parkinsonian disorders.

Early diagnosis may become increasingly important once the genetic contribution to parkinsonian disorders is fully understood. SPECT imaging is beginning to make important contributions to the understanding of the pathogenesis of PD, and may be able to elucidate the role of other neurotransmitter systems, such as NMDA and GABA, in the onset and progression of PD. The screening of “at-risk” subjects before they present with clinical symptoms may be an effective preventative measure, particularly now neuroprotective therapies are becoming available. Longitudinal studies of patients undergoing treatment, whether by neuroprotective drugs or surgical intervention, will become increasingly important in the assessment of treatment efficacy, and also to determine the exact mode of action of each therapy.

The next few years should provide some important and exciting advances in the understanding and treatment of parkinsonian disorders, and SPECT imaging will play a key role in these investigations.

Acknowledgements

The authors are indebted to Dr. Jim Patterson of the Institute of Neurological Sciences, Glasgow, Scotland, for kindly providing several SPECT images for this review.

References


N. Quinn, Multiple system atrophy – the nature of the beast, *Journal of Neurology, Neurosurgery and Psychiatry* 52 (1989), 78–89.


P.D. Acton and P.D. Mozley / Single photon emission tomography imaging in parkinsonian disorders: a review


Submit your manuscripts at http://www.hindawi.com